Celularity (NASDAQ:CELU) Trading Down 0.5% – Here’s Why

Celularity Inc. (NASDAQ:CELUGet Free Report) shares dropped 0.5% during trading on Friday . The company traded as low as $2.10 and last traded at $2.16. Approximately 22,452 shares traded hands during trading, a decline of 72% from the average daily volume of 78,825 shares. The stock had previously closed at $2.17.

Celularity Trading Down 0.5 %

The stock has a fifty day moving average of $2.39 and a 200 day moving average of $2.64.

Celularity (NASDAQ:CELUGet Free Report) last released its earnings results on Wednesday, October 16th. The company reported ($1.03) EPS for the quarter. The business had revenue of $14.68 million for the quarter. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.

About Celularity

(Get Free Report)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

See Also

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.